 An advisory panel to the Japanese drug regulator is continuing deliberations on the new drug application filed by Biogen Inc. BIIB, -0.97 and partner Eisai Co. Ltd ESALY, 0.69 4523, 1.21 , the companies said Wednesday. The NDC New Drugs Committee is seeking additional data to be submitted as part of this process, said the statement. 